Iatrogenic and Toxic Injury

  • Carlos W. M. Bedrossian

Abstract

The lung responds in only a limited number of ways to a variety of injuries. Therefore, most of the reactions described may have more than one cause, and at times it is difficult to identify iatrogenic or toxic agents as possible causes. Such agents may be liquid, solid, or gaseous, and range in chemical composition from very small molecules to large and highly complex compounds that may enter the lung through the airway or reach it via the circulation. (In the case of ratiotherapy, injury may occur by a transthoracic route.) Regardless of the route, the harmful agent eventually affects the delicate interface between air and blood represented by the alveolar septal membrane (see Chapter 2). It is no surprise, then, that the endothelium and the epithelium of the alveolar walls are the primary targets of iatrogenic and toxic substances.1 Because of the limited ways in which these cells respond to the insult and the fact that microscopic findings do not come wearing etiologic labels, the diagnosis of pulmonary toxicity relies heavily on eliciting a clear-cut history associating the harmful agent with subsequent development of pulmonary damage.

Keywords

Interstitial Pneumonia Alveolar Epithelial Cell Radiation Pneumonitis Usual Interstitial Pneumonia Diffuse Alveolar Damage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bedrossian CWM. Pathology of drug-induced lung diseases. Semin Respir Med. 1982; 4: 98 – 102.Google Scholar
  2. 2.
    Cooper JAD Jr, White DA, Matthay RA. Drug-induced pulmonary disease: Part 1: cytotoxic drugs. Am Rev Respir Dis 1986; 133: 321 – 340.PubMedGoogle Scholar
  3. 3.
    Cooper JAD Jr, White DA, Matthay RA. Drug-induced pulmonary disease: Part 2: non-cytotoxic drugs. Am Rev Respir Dis 1986; 183: 488 – 505.Google Scholar
  4. 4.
    Weston JT, Liebow AA, Dixon MG, Rich TH. Untoward effects of exogenous inhalants on the lung. J Forensic Sci 1972; 17: 199 – 279.PubMedGoogle Scholar
  5. 5.
    Lampert-Benignus E, Eichler-Reiss F, Meunier-Carius J, Keiling R. Pulmonary function assessment during bleomycin therapy. Biomed Pharmacother 1985; 39: 8793.Google Scholar
  6. 6.
    Bedrossian CWM, Corey BJ. Abnormal sputum cytology during chemotherapy with bleomycin. Acta Cytol (Baltimore) 1978; 22: 202 – 207.Google Scholar
  7. 7.
    Daniele RP, Elias JA, Epstein PE, Rossman MD. Bronchoalveolar lavage: role in the pathogenesis, diagnosis and management of interstitial lung disease. Ann Intern Med 1985; 102: 93 – 108.PubMedGoogle Scholar
  8. 8.
    Iacovino J, Leitner J, Abbas A, Lokich JL, Snider GL. Fatal pulmonary reaction from low-dose of bleomycin: an idiosyncratic tissue response. JAMA 1976; 235: 1253 – 1258.PubMedGoogle Scholar
  9. 9.
    Shapiro S, Sloane O, Lewis GP, Jick H. Fatal drug reactions among medical in-patients. JAMA 1971; 216: 467–472.Google Scholar
  10. 10.
    Ginsburg WW. Drug-induced systemic lupus erythematosus. Semin Respir Med 1980; 2: 51 – 58.Google Scholar
  11. 11.
    Gillet DG, Ford GT. Drug-induced lung disease. In: Thurlbeck WM, Abell MR, eds. The lung: structure, function and disease. Baltimore: Williams & Wilkins, 1978: 21 – 42.Google Scholar
  12. 12.
    Katzenstein A, Bloor C, Liebow AA. Diffuse alveolar damage: the role of oxygen, shock, and related factors. Am J Pathol 1976; 85: 210 – 226.Google Scholar
  13. 13.
    Gould VE, Miller J. Sclerosing alveolitis induced by cyclophosphamide. Am J Pathol 1975; 81: 513 – 530.PubMedGoogle Scholar
  14. 14.
    Bedrossian CWM, Greenberg SD, Yawn DH, O'Neal RM. Experimentally induced bleomycin sulfate pulmonary toxicity. Arch Pathol Lab Med 1977; 101: 245 – 254.Google Scholar
  15. 15.
    Sostman H, Matthay R, Putnan C. Cytotoxic drug-induced lung disease. Am J Med 1977; 62: 608 – 619.PubMedGoogle Scholar
  16. 16.
    Weiss RB, Muggia FM. Cytotoxic drug-induced lung disease: Update 1980. Am J Med 1980; 68: 259 – 266.Google Scholar
  17. 17.
    Rosenow EC. The spectrum of drug-induced pulmonary disease. Ann Intern Med 1972; 77: 977 – 991.PubMedGoogle Scholar
  18. 18.
    Cole P. Drug-induced lung disease. Drugs 1977; 13: 422–444.Google Scholar
  19. 19.
    Bedrossian CWM, Luna MA, Mackay B, Lichtiger B. Ultrastructure of pulmonary bleomycin toxicity. Cancer 1973; 32: 44 – 51.PubMedGoogle Scholar
  20. 20.
    Freeman BA, Crapo JD. Biology of disease: free radials and tissue injury. Lab Invest 1982; 47: 412 – 426.PubMedGoogle Scholar
  21. 21.
    Lauterburg BH, Smith CV, Mitchell JR. Molecular mechanism involved in drug-induced pulmonary injuries. Semin Respir Med 1980; 2: 45 – 50.Google Scholar
  22. 22.
    Copeland GM, Kolin A, Shulman HS. Fatal pulmonary intraalveolar fibrosis after paraquat ingestion. N Engl J Med 1974; 291: 290 – 292.Google Scholar
  23. 23.
    Deardon LC, Fairshter RD, McRae DM, Smith WR, Glauser FL, Wilson AF. Pulmonary ultrastructure of the late aspects of human paraquat poisoning. Am J Pathol 1978; 93: 667 – 676.Google Scholar
  24. 24.
    Liebow AA. Definition and classification of interstitial pneumonia in human pathology. Prog Respir Res 1975; 8: 1 – 32.Google Scholar
  25. 25.
    Clarysse AM, Corthey WJ, Cartwright GE, Wintrobe MM. Pulmonary disease complicating intermittent therapy with methotrexate. JAMA 1969; 209: 1861 – 1864.PubMedGoogle Scholar
  26. 26.
    Bedrossian CWM, Miller WC, Luna MA. Methotrexateinduced diffuse interstitial pulmonary fibrosis. South Med J 1979; 72: 313 – 318.PubMedGoogle Scholar
  27. 27.
    Luna MA, Bedrossian CWM, Lichtiger B, Salem P. Interstitial pneumonitis associated with bleomycin therapy. Am J Clin Pathol 1972; 58: 501 – 510.PubMedGoogle Scholar
  28. 28.
    Holoye PY, Luna MA, Mackay B, Bedrossian CWM. Bleomycin hypersensitivity pneumonitis. Ann Intern Med 1978; 88: 47 – 49.PubMedGoogle Scholar
  29. 29.
    Jones SE, Moore M, Blank W, Castellino RA. Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary reaction. Cancer 1972; 29: 498–500.Google Scholar
  30. 30.
    Ginsbery SJ, Comis RL. The pulmonary toxicity of autineoplastic agents. Semin Oncol 1982; 9: 34 – 51.Google Scholar
  31. 31.
    Bailey C, Marsden H, Jones P. Fatal pulmonary fibrosis following 1,3-BIS 2-chloroethyl 7-nitroso urea (BCNU) therapy. Cancer 1978; 42: 74 – 79.PubMedGoogle Scholar
  32. 32.
    Mark G, Lehimgar-Zadeh A, Ragsdale B. Cyclophosphamide pneumonitis. Thorax 1978; 33: 89 – 94.PubMedGoogle Scholar
  33. 33.
    Bauer KA, Skarin AT, Balikian JP, Garnick MB, et al. Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med 1983; 74: 557 – 563.PubMedGoogle Scholar
  34. 34.
    Löffler W. Zur differential-diagnose der lungen in fil-trierungen, II: Über flüchtige succedan-infiltrate (miteosinophilie). Beitr Klin Tuberk 1932; 79: 368 – 382.Google Scholar
  35. 35.
    Bedrossian CWM, Greenberg SD, Williams LG. Ultra-structure of the lung in Loeffler's pneumonitis. Am J Med 1975; 58: 438–443.Google Scholar
  36. 36.
    Holmberg I, Boman G, Bottiger LE, Erikson B, et al. Adverse reactions to nitrofurantoin: analysis of 921 reports. Am J Med 1980; 69: 733 – 738.PubMedGoogle Scholar
  37. 37.
    White DA, Gellene R, Rankin JR, Gupta S, et al. Methotrexate pneumonitis: bronchoalveolar lavage findings suggestive of an immune-mediate disorder. Am Rev Respir Dis 1984; 129: A64.Google Scholar
  38. 38.
    Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of the lung: clinical aspects of primary pulmonary histiocytosis in the adult. Medicine (Baltimore) 1981; 60: 385 – 396.Google Scholar
  39. 39.
    Webber D, Tron V, Askin F, Churg A. S-100 staining in the diagnosis of eosinophilic granuloma of the lung. Am J Clin Pathol 1985; 84: 447 – 453.PubMedGoogle Scholar
  40. 40.
    Kochar A. Human pulmonary dirofilariasis: report of three cases and brief review of the literature. Am J Clin Pathol 1985; 84: 19 – 23.PubMedGoogle Scholar
  41. 41.
    Hunninghake GW, Fauci AS. Pulmonary involvement in collagen vascular diseases. Am Rev Respir Dis 1979; 119: 471 – 503.PubMedGoogle Scholar
  42. 42.
    Kawanami O. Hypersensitivity pneumonitis in man: light and electron microscopic studies of 18 lung biopsies. Am J Pathol 1983; 110: 275 – 289.PubMedGoogle Scholar
  43. 43.
    Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977; 86: 405 – 410.PubMedGoogle Scholar
  44. 44.
    Jelihovsky T. The structure of bronchial plugs in mucoid impaction, bronchocentric granulomatosis and asthma. Histopathology 1983; 7: 153 – 168.PubMedGoogle Scholar
  45. 45.
    Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258: 1123 – 1142.PubMedGoogle Scholar
  46. 46.
    Martin RJ, Coalson JJ, Rogers RM, Horton FO, Manous LE. Pulmonary alveolar proteinosis: the diagnosis by segmental lavage. Am Rev Respir Dis 1980; 121: 819 – 825.PubMedGoogle Scholar
  47. 47.
    Bedrossian CWM, Luna MA, Conklin RH, Miller WC. Alveolar proteinosis as a consequence of immunosuppression: a hypothesis based on clinical and pathological observations. Hum Pathol 1980; 11: 527 – 535.PubMedGoogle Scholar
  48. 48.
    Singh G, Katyal SL, Bedrossian CWM, Rogers RM. Pulmonary alveolar proteinosis: staining for surfactant apoprotein in alveolar proteinosis and conditions simulating it. Chest 1983; 83: 82 – 86.PubMedGoogle Scholar
  49. 49.
    Back O, Liden S, Abistedt S. Adverse reaction to mitrofurantoin in relation to cellular and humoral immune mechanisms. Clin Exp Immunol 1977; 28: 400 – 406.PubMedGoogle Scholar
  50. 50.
    Yoshizawa Y, Ohdama S, Ikeda A, Ohtsuka M, Masuda S, Tanaka M. Lymphoid interstitial pneumonia associated with depressed cellular immunity and polyclonal gammopathy. Am Rev Respir Dis 1984; 130: 507 – 509.PubMedGoogle Scholar
  51. 51.
    Stover DE, White DA, Romano PA, Gellene RA, Robeson WA. Spectrum of pulmonary disease associated with the acquired immunodeficiency syndrome. Am J Med 1985; 78: 429 – 437.PubMedGoogle Scholar
  52. 52.
    Rankin JA, Walzer DD, Dwyer JM, Schrader CE, Enriquez RE, Merrill KW. Immunologic alterations in bronchoalveolar lavage fluid in acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1983; 128: 189–194.Google Scholar
  53. 53.
    Danel C, Dewar A, Corrin B, Turner-Warwick M, Chretien J. Ultrastructural changes in bronchoalveolar lavage cells in sarcoidosis and comparison with the tissue granuloma. Am J Pathol 1983; 112: 7 – 17.PubMedGoogle Scholar
  54. 54.
    Marchevsky A, Padilla M, Kaneko M, Kleinerman J. Localized lymphoid nodules of the lung: a reappraisal of the lymphoma vs. pseudolymphoma dilemma. Cancer 1983; 51: 2070 – 2077.PubMedGoogle Scholar
  55. 55.
    Weinstein A. Drug-induced systemic lupus erythematosis. Prog Clin Immunol 1980; 4: 1 – 21.PubMedGoogle Scholar
  56. 56.
    Byrd RB, Scharizer B. Pulmonary sequelae in procainomide-induced lupus-like syndrome. Dis Chest 1969; 55: 170 – 172.PubMedGoogle Scholar
  57. 57.
    Alarcon-Segovia D. Drug-induced lupus syndromes. Mayo Clin Proc 1969; 44: 664 – 681.PubMedGoogle Scholar
  58. 58.
    Sack KE, Kekheit S, Fadem SZ, Bedrossian CWM. Severe pulmonary vascular disease in S.L. E. South Med J 1979; 72: 1016 – 1018.Google Scholar
  59. 59.
    Blomgren SE, Condeme JJ, Vaughan JH. Procainamideinduced lupus erythematosus: clinical and laboratory observations. Am J Med 1972; 52: 538 – 548.Google Scholar
  60. 60.
    Kay JM, Smith P, Heath D. Aminorex and the pulmonary circulation. Thorax 1971; 26: 262 – 270.PubMedGoogle Scholar
  61. 61.
    Culvenor CC, Edgar JA, Jago MV, Qutteridge A, Petersen JE, Smith LW. Hepato-and pneumotoxicity of pyrrolizidine alkaloids and derivatives in relation to molecular structure. Chem Biol Interact 1976; 12: 229 – 324.Google Scholar
  62. 62.
    Miller WC, Rice DL, Kreusel RG, Bedrossian CWM. Monocrotaline model of non-cardiogenic pulmonary edema in dogs. J Appl Physiol 1978; 45: 962 – 965.PubMedGoogle Scholar
  63. 63.
    Tomashefski JE, Hirsh CS. The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol 1980; 11: 133 – 145.PubMedGoogle Scholar
  64. 64.
    Moskowitz RL. Talc pneumonoconiosis: a treated case. Chest 1970; 48: 37 – 41.Google Scholar
  65. 65.
    Liebow AA, Steer A, Billingsley JG. Desquamative interstitial pneumonia. Am J Med 1965; 39: 369 – 404.PubMedGoogle Scholar
  66. 66.
    Fromm GB, Dunn LJ, Harris JO. Desquamative interstitial pneumonitis: characterization of free intraalveolar cells. Chest 1980; 77: 552 – 558.PubMedGoogle Scholar
  67. 67.
    Carrington CB, Gaensler EA, Coutu RE, Fitzgerald MX, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801 – 809.PubMedGoogle Scholar
  68. 68.
    Tubbs RR, Benjamin SP, Reich NF, et al. Desquamative interstitial pneumonitis: cellular phase of fibrosing alveolitis. Chest 1977; 72: 159 – 165.PubMedGoogle Scholar
  69. 69.
    Bedrossian CWM. Desquamative interstitial pneumonia versus usual interstitial pneumonia. Chest 1978; 73: 559 – 560.Google Scholar
  70. 70.
    Bone RC, Wolfe J, Sobonya RE, et al. Desquamative interstitial pneumonia following long-term nitrofurantous therapy. Am J Med 1976; 60: 697 – 702.PubMedGoogle Scholar
  71. 71.
    Frankel LS, Atkins FM, Flake GP, Ayala A, Bedrossian CWM. DIP following chemotherapy for acute leukemia. Am J Pediatr Hematol Oncol 1980; 2: 103 – 109.Google Scholar
  72. 72.
    Smith P, Heath D, Hasleton PS. Electron microscopy of chlorphentermine lung. Thorax 1973; 28: 559 – 566.PubMedGoogle Scholar
  73. 73.
    Rakita L, Sobol SM, Mostow N, Urobel T. Amiodarone pulmonary toxicity. Am Heart J 1983; 106: 906 – 916.PubMedGoogle Scholar
  74. 74.
    Corrin B, Price AB. Electron microscopic studies in desquamative interstitial pneumonia associated with asbestos. Thorax 1972; 27: 324 – 328.PubMedGoogle Scholar
  75. 75.
    Fitzgerald MX, Carrington CB, Gaensler EA. Environmental lung disease. Med Clin North Am 1973; 57: 593 – 622.PubMedGoogle Scholar
  76. 76.
    Turner-Warwick M. Diffuse interstitial disease of the lungs. In Stretton TB (ed.) Recent advances in respiratory medicine. Edinburgh: Churchill Livingston, 1976: 187 – 209.Google Scholar
  77. 77.
    Bedrossian CWM, Kuhn C III, Luna MA, Conklin RH, Byrd RB, Koplan PD. Desquamative interstitial pneumonia-like reaction accompanying pulmonary lesions. Chest 1977; 72: 166 – 169.PubMedGoogle Scholar
  78. 78.
    Mark E. Lung biopsy interpretation. Baltimore: Williams & Wilkins 1984: 103 – 112.Google Scholar
  79. 79.
    Kinjo M, Watanabe T, Tanaka K. Localized form of desquamative interstitial pneumonia. Chest 1974; 65: 458 – 460.PubMedGoogle Scholar
  80. 80.
    Lipinski J, Weisbrod G, Sanders D. Exogenosis lipoid pneumonitis: pulmonary patterns. AJR 1981; 136: 931 – 938.PubMedGoogle Scholar
  81. 81.
    Heckers H, Melcher FW, Dittmar K, Knorrp K, Nekarda K. Long-term course of mineral oil pneumonia. Lung 1978; 155: 101 – 109.PubMedGoogle Scholar
  82. 82.
    Fox B. Liquid paraffin pneumonia with chemical analysis and electron microscopy. Virch Arch [A] 1979; 382: 339 – 346.Google Scholar
  83. 83.
    Borrie J, Gwynne JF. Paraffinoma of the lung: lipoid pneumonia. Report of two cases. Thorax 1973; 28: 214 – 217.PubMedGoogle Scholar
  84. 84.
    De Nevasquez S, Haslewood GAD. Endogenous lipid pneumonia with reference to carcinoma of the lung. Thorax 1954; 9: 35 – 39.Google Scholar
  85. 85.
    Harris L, McKenna WS, Rowland E, Krikler DM. Side effects and possible contraindications of amiodarone use. Am Heart J 1983; 106: 916 – 921.PubMedGoogle Scholar
  86. 86.
    Dake M, Madison JM, Montgomery CK, et al. Electron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes and blood leukocytes of patients with amiodarone pulmonary toxicity. Am J Med 1985; 78: 506 – 511.PubMedGoogle Scholar
  87. 87.
    Liu FL-W, Cohen RD, Downar E, Butany JW, Edelson JD, Rebuck AS. Amiodarone toxicity: functional and ultrastructural evaluation. Thorax 1986; 41: 100 – 105.PubMedGoogle Scholar
  88. 88.
    Akoum GM, Gauthier-Rahman S, Milleron BJ, Perrot JY, Mayaud CM. Amiodarone-induced interstitial pneumonitis: evidence of an immunological cell-mediated mechanism. Chest 1984; 85: 133 – 135.Google Scholar
  89. 89.
    Weil MH, Henning RJ, Moresette M, Michaels S. Relationship between colloidal osmotic pressure and pulmonary artery wedge pressure in patients with acute cardio respiratory failure. Am J Med 1978; 64: 643 – 650.PubMedGoogle Scholar
  90. 90.
    Staub NC. Pulmonary edema. Physiol Rev 1974; 54: 678 – 686.PubMedGoogle Scholar
  91. 91.
    Rinehart JR, Lewis RP, Balcerzak SP. Adriamycin cardiotoxicity in man. Ann Intern Med 1974; 81: 475 – 478.PubMedGoogle Scholar
  92. 92.
    Rice DL, Bedrossian CWM, Blair T, Miller WC. Closing volumes with variations in pulmonary capillary wedge pressure. Am Rev Respir Dis 1981; 123: 513 – 516.PubMedGoogle Scholar
  93. 93.
    Steinberg AD, Karliner JS. The clinical spectrum of heroin pulmonary edema. Arch Intern Med 1968; 122: 122 – 127.PubMedGoogle Scholar
  94. 94.
    Smith WR, Wells ID, Glauser FL, Novey HS. Immunologic abnormalities in heroin lung. Chest 1975; 68: 651 – 653.Google Scholar
  95. 95.
    Irey NS, Froede RC. Evaluation of deaths from drug overdose: a clinicopathologic study. Am J Clin Pathol 1974; 61: 778 – 784.PubMedGoogle Scholar
  96. 96.
    Smith WR, Dearden LC, McRae DM. Deposits of immunoglobulin and complement in the pulmonary tissue of patients with “Heroin Lung. ” Chest 1978; 73: 471 – 476.PubMedGoogle Scholar
  97. 97.
    Haupt HM, Hutchins GM, Moore GW. Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia. Am J Med 1981; 70: 256 – 261.PubMedGoogle Scholar
  98. 98.
    Lascari AD, Strano AJ, Johnson WW, Collins JGP. Methotrexate-induced sudden fatal pulmonary reaction. Cancer 1977; 40: 1393 – 1397.PubMedGoogle Scholar
  99. 99.
    Maxwell I. Reversible pulmonary edema following cyclophosphamide treatment. JAMA 1974; 229: 137 – 138.PubMedGoogle Scholar
  100. 100.
    Frank L, Massaro D. Oxygen toxicity. Am J Med 1980; 69: 117 – 124.PubMedGoogle Scholar
  101. 101.
    Barber R, Lee J, Hamilton W. Oxygen toxicity in man: a prospective study in patients with irreversible brain damage. N Engl J Med 1970; 283: 1478 – 1483.PubMedGoogle Scholar
  102. 102.
    De la Monte SM, Hutchings GM, Moore GW. Respiratory epithelial cell necrosis is the earliest lesion of hyaline membrane disease of the newborn. Am J Pathol 1986; 123: 155 – 160.PubMedGoogle Scholar
  103. 103.
    Pappas CTE, Obara H, Bensch KG, Northway WH. Effect of prolonged exposure to 80% oxygen on the lung of the newborn mouse. Lab Invest 1983; 48: 735 – 748.PubMedGoogle Scholar
  104. 104.
    Bonikos D, Bensch K, Northway W Jr, Edwards D. Bronchopulmonary dysplasia: the pulmonary pathologic se-qual of necrotizing bronchiolitis and pulmonary fibrosis. Hum Pathol 1976; 7: 643 – 649.PubMedGoogle Scholar
  105. 105.
    Pratt PC. Pathology of pulmonary oxygen toxicity. Am Rev Respir Dis 1974; 110 (6 Pt 2 Suppl): 51 – 57.PubMedGoogle Scholar
  106. 106.
    Stephens RJ, Sloan MA, Evans MJ, Freeman G. Early response of lungs to low levels of ozone. Am J Pathol 1974; 74: 31 – 58.PubMedGoogle Scholar
  107. 107.
    Zitnik LA, Schwartz LW, McQuillen NK, Zee YC, Ose-bold JW. Pulmonary changes induced by low-level ozone: morphologic observations. J Environ Pathol Toxicol Oncol 1978; 1: 365 – 376.Google Scholar
  108. 108.
    Yven TGH, Sherwin RP. Hyperplasia of type 2 pneumo cytes and nitrogen dioxide (10 ppm) exposure. Arch Environ Health 1971; 22: 178 – 188.Google Scholar
  109. 109.
    Charan N, Myers G, Lakshminarayan S, Spencer T. Pulmonary injuries associated with acute sulfur inhalation. Am Rev Respir Dis 1979; 555 – 560.Google Scholar
  110. 110.
    Sobonya R. Fatal anhydrous ammonia inhalation. Hum Pathol 1977; 8: 293 – 299.PubMedGoogle Scholar
  111. 111.
    Cucinell SA, Arsenal E. Review of toxicity of long-term phosgene exposure. Arch Environ Health 1974; 28: 272 – 275.PubMedGoogle Scholar
  112. 112.
    Decker WJ, Koch HF. Chlorine poisoning at the swimming pool: an overlooked hazard. Clin Toxicol 1978; 13: 377 – 381.PubMedGoogle Scholar
  113. 113.
    Hasleton PS. The lung parenchyma in burns. Histopathology 1983; 7: 333 – 348.PubMedGoogle Scholar
  114. 114.
    Hoeffler HB, Schweppe HI, Greenberg SD. Bronchiectasis following a pulmonary ammonia burn. Arch Pathol Lab Med 1982; 106: 686 – 687.PubMedGoogle Scholar
  115. 115.
    Greenberg SD, Gyorkey F, Jenkins DE, Gyorkey P. Alveolar epithelial cells following exposure to nitric acid. Arch Environ Health 1971; 22: 655 – 662.PubMedGoogle Scholar
  116. 116.
    Williams MK. Sickness, absence and ventilatory capacity of workers exposed to sulfuric acid mist. Br J Ind Med 1970; 27: 61 – 65.PubMedGoogle Scholar
  117. 117.
    Ramirez-RJ, Dowell AR. Silo-fillers disease: nitrogen dioxide-induced lung injury. Ann Intern Med 1971; 74: 569 – 576.Google Scholar
  118. 118.
    Morrissey WL, Gould IA, Carrington CB, et al. Silo-filler's disease. Respiration 1975; 32: 81 – 92.PubMedGoogle Scholar
  119. 119.
    Lake J, Paul E, Virgulto JA, Smith GJW. Rabbit lung after acute smoke inhalation: cellular responses and scanning electron microscopy. Arch Surg 1984; 119: 956 – 959.Google Scholar
  120. 120.
    Zikria BA, Ferrer JM, Floch HF. The chemical factors contributing to pulmonary damage in “smoke poisoning. ” Surgery 1972; 71: 704 – 709.PubMedGoogle Scholar
  121. 121.
    Beton DC, Andrews GS, Davies HJ, et al. Acute cadmium fume poisoning. Five cases with one death from renal necrosis. Br J Ind Med 1966; 23: 292 – 301.PubMedGoogle Scholar
  122. 122.
    Halle TJ. Diffuse lung disease caused by inhalation of mercury vapor. Am Rev Respir Dis 1969; 99: 430 – 436.Google Scholar
  123. 123.
    Johnson FA, Stonehill RB. Chemical pneumonitis from inhalation of zinc chloride. Dis Chest 1961; 40: 619 – 624.PubMedGoogle Scholar
  124. 124.
    Abraham, JL. Recent advances in pneumonoconiosis: the pathologist's role in etiologic diagnosis. In: Thurlbeck WM, Abell MR, eds. The lung: structure, function and disease, Baltimore: Williams & Williams, 1978: 128 – 138.Google Scholar
  125. 125.
    Gough J. Emphysema in relation to occupation. Ind Med Surg 1960; 29: 283 – 285.Google Scholar
  126. 126.
    Freiman DG, Hardy HL. Beryllium disease. Hum Pathol 1970; 1: 25 – 44.PubMedGoogle Scholar
  127. 127.
    Jones Williams WJ. The nature and origin of Schaumann bodies. J Pathol Bacteriol 1960; 1: 193 – 201.Google Scholar
  128. 128.
    Deodhar SD, Barna B, Von Ostraud HS. A study of the immunologic aspects of chronic berylliosis. Chest 1973; 309 – 313.Google Scholar
  129. 129.
    Milliken JA, Waugh D, Kadish ME. Acute interstitial pulmonary fibrosis caused by a smoke bomb. Can Med Assoc J 1963; 88: 36 – 39.PubMedGoogle Scholar
  130. 130.
    McCormick J, Cole S, Lahirir B, Knauft F, Cohen S, Yoshida T. Pneumonitis caused by gold salt therapy: evidence for a cell-mediated immunity in its pathogenesis. Am Rev Respir Dis 1980; 122: 145 – 152.PubMedGoogle Scholar
  131. 131.
    Gross N. Pulmonary effects of radiation therapy. Ann Intern Med 1977; 86: 81 – 92.PubMedGoogle Scholar
  132. 132.
    Fajardo LF, Berthrong M. Radiation injury in surgical pathology. Am J Surg Pathol 1978; 2: 159 – 199.PubMedGoogle Scholar
  133. 133.
    Roswit B, White DC. Severe radiation injuries of the lung. AJR 1977; 129: 127 – 136.PubMedGoogle Scholar
  134. 134.
    Castellino RA, Glatstein E, Turbow MM, Rosenberg S, Kaplan HS. Latent radiation injury of the lung or heart activated by steroid withdrawal. Ann Intern 1974; 80: 593 – 599.Google Scholar
  135. 135.
    Einhorn L, Krause M, Hornback N, Fumas B. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer 1976; 37: 2414 – 2416.PubMedGoogle Scholar
  136. 136.
    Braun S, do Pico G, Olson C, Caldwell W. Low-dose radiation pneumonitis. Cancer 1974; 35: 1322 – 1324.Google Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Carlos W. M. Bedrossian

There are no affiliations available

Personalised recommendations